Wall Street analysts expect that Jazz Pharmaceuticals (NASDAQ:JAZZ) will announce $434.41 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $448.38 million and the lowest estimate coming in at $426.50 million. Jazz Pharmaceuticals posted sales of $376.05 million in the same quarter last year, which suggests a positive year over year growth rate of 15.5%. The firm is expected to issue its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.89 billion for the current fiscal year, with estimates ranging from $1.87 billion to $1.90 billion. For the next fiscal year, analysts expect that the business will post sales of $2.15 billion per share, with estimates ranging from $2.06 billion to $2.21 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. The company had revenue of $436.40 million during the quarter, compared to analyst estimates of $440.91 million.
Several brokerages have commented on JAZZ. BidaskClub raised shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $128.58 to $163.75 in a research report on Monday, March 19th. Deutsche Bank set a $170.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 16th. Seaport Global Securities set a $175.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, April 6th. Finally, HC Wainwright reissued a “neutral” rating and issued a $160.00 price target (up previously from $150.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 23rd. Six analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $180.78.
In other news, SVP Karen J. Wilson sold 3,899 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $155.00, for a total transaction of $604,345.00. Following the completion of the sale, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. Following the sale, the chief executive officer now directly owns 267,468 shares of the company’s stock, valued at $40,120,200. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,957 shares of company stock valued at $2,080,782. Corporate insiders own 4.30% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its stake in Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after acquiring an additional 360 shares in the last quarter. We Are One Seven LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $157,000. Invictus RG acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $206,000. Ladenburg Thalmann Financial Services Inc. raised its stake in Jazz Pharmaceuticals by 795.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 1,551 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after acquiring an additional 400 shares in the last quarter. 91.21% of the stock is owned by institutional investors and hedge funds.
JAZZ stock traded up $1.63 during midday trading on Tuesday, hitting $157.59. The company’s stock had a trading volume of 548,947 shares, compared to its average volume of 439,146. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.57. Jazz Pharmaceuticals has a 52-week low of $128.58 and a 52-week high of $163.75. The stock has a market capitalization of $9,333.52, a PE ratio of 16.48, a P/E/G ratio of 0.82 and a beta of 0.97.
COPYRIGHT VIOLATION WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/18/brokerages-expect-jazz-pharmaceuticals-jazz-will-announce-quarterly-sales-of-434-41-million.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.